Bristol-Myers Squibb Company

(New York Stock Exchange)
Back to all articles
Bullish +55

Bristol Myers (BMY) Stock is Trading Below 10 Times Forward Earnings. Hereโ€™s Why it Matters

Company update Dividend Earnings report AI-generated analysis

๐Ÿ“ˆ Bristol Myers' Growth Portfolio generated $7.6 billion in Q2 2026 revenue, a 15% increase year-over-year, now comprising nearly 60% of total revenue.

๐Ÿ’ฐ Total company revenue reached $12.97 billion in the quarter, up 6%, while Non-GAAP EPS surged 40% to $2.04.

๐Ÿš€ The company raised its 2026 full-year guidance to expect $49-$50 billion in revenue and $6.75-$7.00 in Non-GAAP EPS.

๐Ÿ’Š Key growth drivers Reblozyl, Camzyos, Breyanzi, Opdualag, and Eliquis all posted revenue increases, with Eliquis up 22%.

โš ๏ธ Legacy drug revenue declined 4% due to generic competition, underscoring the critical need for newer portfolio growth.

๐Ÿ“‰ The stock trades at 9.4 times forward earnings, reflecting a valuation that has recovered from earlier patent-cliff concerns but remains below 10x.

๐Ÿ’ต Bristol Myers offers an annualized dividend of $2.52 per share, yielding approximately 4.1% with a payout ratio around 55%.

๐Ÿ›ก๏ธ The company maintains a strong moat through intellectual property, drug development capabilities, and global sales infrastructure.

๐Ÿ“… Morningstar forecasts 2028 as a significant patent-loss year, requiring new launches to offset revenue from expiring older medicines.

Bullish Signals
  • Bristol Myers' Growth Portfolio grew 15% year-over-year to $7.6 billion in Q2 2026, now representing nearly 60% of total revenue.
  • Non-GAAP EPS increased 40% to $2.04 in the quarter, demonstrating strong profitability from newer medicines.
  • The company raised its 2026 full-year guidance, projecting revenue between $49 billion and $50 billion.
  • Eliquis revenue increased 22% during the quarter, continuing to serve as a major contributor to top-line growth.
  • Opdivo Qvantig revenue jumped more than 200%, indicating strong uptake in this newer oncology product.
  • The stock trades at 9.4 times forward earnings, suggesting the market has adjusted its valuation away from severe patent-cliff fears.
  • Bristol Myers offers an attractive dividend yield of roughly 4.1% with a sustainable payout ratio of around 55%.
Risk Factors
  • Legacy drug revenue declined 4% in the quarter as generic competition intensified for several established products.
  • Eliquis and Opdivo face longer-term patent expiration concerns that could impact future revenue streams.
  • Morningstar expects 2028 to be a major patent-loss year, creating pressure on the company to offset declines with new launches.
Full Analysis
Bristol-Myers Squibb (NYSE:BMY) is navigating a critical transition period where its investment story is shifting from reliance on older blockbuster drugs facing patent expiration to newer medicines driving growth. The company's latest financial results indicate progress in this strategic pivot, with its Growth Portfolio generating $7.6 billion in revenue during the second quarter of 2026, representing a 15% year-over-year increase and now accounting for nearly 60% of total revenue. The company reported total revenue of $12.97 billion for the quarter, up 6% year over year, while Non-GAAP EPS climbed 40% to $2.04. Consequently, Bristol Myers raised its full-year 2026 outlook, projecting revenue between $49 billion and $50 billion and Non-GAAP EPS between $6.75 and $7.00. Key growth drivers include Reblozyl, Camzyos, Breyanzi, Opdualag, and Eliquis, with Eliquis revenue increasing 22% in the quarter. Despite the positive momentum from newer drugs, legacy revenue declined 4% due to generic competition, highlighting the necessity of the portfolio shift. The stock trades at approximately 9.4 times forward earnings and offers a dividend yield of roughly 4.1%, positioning it as an attractive high-yield pharmaceutical investment with a solid moat built on intellectual property and scale, though investors must monitor if new drug growth can fully offset future patent losses.